SCHEMBL19986923

SCHEMBL19986923

CC(C)(O)C1CCC(Nc2ccn3ncc(-c4cccc(OC(F)(F)F)c4)c3n2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 20/20 1.00
PIM2 Q9P1W9 14/20 1.00
FLT3 P36888 4/20 0.81
KCNH2 Q12809 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL102044 1.00 PIM1 (1.00) PIM1PIM2FLT3KCNH2
SCHEMBL102174 0.89 PIM1 (1.00) PIM1PIM2FLT3KCNH2
SCHEMBL134840 0.89 PIM1 (1.00) PIM1PIM2FLT3KCNH2
SCHEMBL19986965 0.89 PIM1 (0.83) PIM1PIM2FLT3KCNH2
SCHEMBL178350 0.88 PIM1 (1.00) PIM1PIM2FLT3KCNH2
SCHEMBL102561 0.88 PIM1 (1.00) PIM1PIM2FLT3KCNH2
SCHEMBL19986964 0.87 PIM1 (0.83) PIM1PIM2FLT3KCNH2
SCHEMBL102925 0.87 PIM1 (1.00) PIM1PIM2FLT3KCNH2
SCHEMBL102858 0.87 PIM1 (1.00) PIM1PIM2FLT3
SCHEMBL20794288 0.87 PIM1 (1.00) PIM1PIM2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2021-08-05 US disclosed
US-10875864-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2020-12-29 US disclosed
US-10392392-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2019-08-27 US disclosed
US-20190071446-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2019-03-07 US disclosed
EP-2734205-B1 HETEROCYCLIC PROTEIN KINASE INHIBITORS TOLERO PHARMACEUTICALS INC (US) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875864-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors PIM2, PIM1, PIM3 PIM1 2/4885PIM2 1/4885FLT3 364/4885
US-20190071446-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885FLT3 120/4885
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885FLT3 120/4885
US-10392392-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885FLT3 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.